We serve Chemical Name:(Z)-2-(4-fluorophenyl)-3-phenylprop-2-enenitrile CAS:2558-28-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(Z)-2-(4-fluorophenyl)-3-phenylprop-2-enenitrile
CAS.NO:2558-28-3
Synonyms:(2Z)-2-(4-Fluorophenyl)-3-phenylacrylonitrile;PC4264;2-(4-Fluorophenyl)-3-phenylacrylonitrile;MFCD05664341;E-|A-(4-Fluorophenyl)cinnamonitrile
Molecular Formula:C15H10FN
Molecular Weight:223.24500
HS Code:
Physical and Chemical Properties:
Melting point:101-105ºC(lit.)
Boiling point:333.1ºC at 760 mmHg
Density:1.174g/cm3
Index of Refraction:1.62
PSA:23.79000
Exact Mass:223.08000
LogP:3.88988
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like (2Z)-2-(4-Fluorophenyl)-3-phenylacrylonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,E-|A-(4-Fluorophenyl)cinnamonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-Fluorophenyl)-3-phenylacrylonitrile Use and application,MFCD05664341 technical grade,usp/ep/jp grade.
Related News: Earlier this month, the drugmaker lifted a voluntary EU marketing hold on Zynteglo for beta thalassemia, after a patient death in one of the drugmaker’s other products, LentiGlobin, halted clinical studies. 3-Fluoro-2-methyl-6-nitroaniline manufacturers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. O-(2,2,2-trifluoroethyl)hydroxylamine suppliers EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. 11(13)-Dehydroivaxillin vendor & factory.
